Abivax (NASDAQ:ABVX - Get Free Report) had its price target upped by research analysts at Piper Sandler from $70.00 to $112.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has an "overweight" rating on the stock. Piper Sandler's price target would suggest a potential upside of 55.69% from the company's current price.
Several other brokerages have also issued reports on ABVX. JMP Securities boosted their price objective on shares of Abivax from $33.00 to $95.00 and gave the company a "market outperform" rating in a report on Wednesday, July 23rd. Guggenheim boosted their price objective on shares of Abivax from $50.00 to $101.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Morgan Stanley upgraded shares of Abivax from an "equal weight" rating to an "overweight" rating and set a $71.00 price objective on the stock in a report on Wednesday, July 23rd. Lifesci Capital boosted their price objective on shares of Abivax from $45.00 to $101.00 and gave the company an "outperform" rating in a report on Wednesday, July 23rd. Finally, Citigroup restated a "market outperform" rating on shares of Abivax in a report on Friday, July 18th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Abivax presently has a consensus rating of "Buy" and a consensus target price of $92.33.
Read Our Latest Analysis on ABVX
Abivax Trading Up 0.2%
Shares of ABVX stock traded up $0.17 on Tuesday, hitting $71.94. 1,252,397 shares of the stock traded hands, compared to its average volume of 3,075,499. The firm's 50-day moving average price is $17.46 and its two-hundred day moving average price is $10.30. The company has a current ratio of 1.25, a quick ratio of 1.25 and a debt-to-equity ratio of 1.29. Abivax has a twelve month low of $4.77 and a twelve month high of $75.51.
Institutional Trading of Abivax
A number of large investors have recently made changes to their positions in the company. ADAR1 Capital Management LLC increased its stake in shares of Abivax by 46.0% during the first quarter. ADAR1 Capital Management LLC now owns 2,210,019 shares of the company's stock worth $13,813,000 after buying an additional 696,626 shares during the period. Nantahala Capital Management LLC increased its stake in Abivax by 3.3% in the first quarter. Nantahala Capital Management LLC now owns 1,482,994 shares of the company's stock valued at $9,269,000 after purchasing an additional 46,947 shares during the last quarter. Franklin Resources Inc. increased its stake in Abivax by 10.7% in the fourth quarter. Franklin Resources Inc. now owns 1,466,062 shares of the company's stock valued at $10,732,000 after purchasing an additional 141,710 shares during the last quarter. Octagon Capital Advisors LP purchased a new position in Abivax in the first quarter valued at approximately $7,688,000. Finally, Allostery Investments LP increased its stake in Abivax by 86.0% in the first quarter. Allostery Investments LP now owns 1,099,654 shares of the company's stock valued at $6,873,000 after purchasing an additional 508,401 shares during the last quarter. 47.91% of the stock is currently owned by hedge funds and other institutional investors.
Abivax Company Profile
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Featured Articles
Before you consider Abivax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.
While Abivax currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access